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Epidemiological and clinical studies suggest that HF with a preserved ejection fraction will become the more
common form of HF which clinicians will encounter. The spectrum of diastolic disease extends from the asymptomatic
phase to fulminant cardiac failure. These patients are commonly encountered in operating rooms and critical care units.
A clearer understanding of the underlying pathophysiology and clinical implications of HF with a preserved ejection
fraction is fundamental to directing further research and to evaluate interventions. This review highlights the impact of
diastolic dysfunction and HF with a preserved ejection fraction during the perioperative period and during critical
illness.
 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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dred thousand new cases are reported every year
[1–3]. Epidemiological and clinical studies have
confirmed the trend of increasing incidence of
chronic HF internationally [4]. HF remains largely
a disease of the elderly and in patients older than
65 years it is the most common diagnosis at hospi-
tal discharge and the most frequent cause of re-
admission [3,5]. Diastolic dysfunction refers to
abnormalities in left ventricular distensibility, fill-
ing or relaxation regardless of signs and symp-
toms of HF or left ventricular ejection fraction
[6]. Diastolic dysfunction in the absence of symp-
toms is common in elderly hypertensive patients
[7]. Heart failure with a preserved ejection fraction
(HFpreEF), or diastolic HF, refers to the clinical
syndrome of HF coupled with evidence of dia-
stolic dysfunction and is estimated to occur in
approximately 50% of patients with chronic HF
[8–12]. In patients older than 70 years, the ad-
justed mortality rate for HFpreEF is equivalent to
those patients with reduced systolic function [8–
12]. It is projected that in the developed world
the proportion of the population >65 years old
and the number of surgical procedures in this
group of patients will increase dramatically with
at least one in two persons undergoing an opera-
tion in the remainder of their lifetime [13]. It is
therefore imperative that anaesthetists and
intensivists appreciate the impact of diastolic dys-
function and HFpreEF on the aging heart. Despite
recent advances in the understanding of HF, there
is little consensus about the definition, prognosis
and treatment of HFpreEF and diastolic dysfunc-
tion. This review aims is to describe the patho-
physiological mechanisms for and highlight the
clinical relevance of diastolic dysfunction and
HFpreEF.Methodology
The literature review was obtained from a com-
puter search of the PUBMED, MEDLINE and
EMBASE databases from 1966 to December2011. A number of different search strategies were
used and articles were restricted to English lan-
guage only. Search terms included ‘diastolic’, dys-
function, ‘heart failure’, ‘sepsis’, ‘critical illness’,
‘paediatrics’, ‘pre-operative’, ‘post-operative’,
‘diabetes’, ‘renal impairment’ and ‘anaesthesia’.
This is a narrative review as the broad spectrum
of topics covered in this review prohibits a fully
systematic approach. Abstracts were screened for
relevance. Additional reports were identified from
reference list screening and relevant systematic
reviews were sought and their findings high-
lighted. Authors were not contacted for additional
information.Definition
The concept of HFpreEF was introduced by
Kessler in 1988 [14]. Subsequently, there have
been numerous attempts to develop diagnostic
criteria; however there has been little consensus
[15–19]. In 1998 Paulus et al. developed the Euro-
pean Criteria for HFpreEF [20]. This group sug-
gested that there must be objective evidence of
HF with a normal or mildly impaired systolic func-
tion (left ventricular ejection fraction
(LVEF) > 45%) and abnormal left ventricular (LV)
relaxation. All three criteria are required for the
diagnosis of HFpreEF. Plasma levels of B-natri-
uretic peptide (BNP) are elevated in patients with
HF, independent of the aetiology of HF [21,22]. An
alternative and simpler definition of HFpreEF is
an elevated BNP with a normal LVEF [23], how-
ever, there may be several limitations to this defi-
nition. Specifically elevated BNP levels have been
found in patients with myocardial ischaemia in
the absence of congestive heart failure (CHF)
[24,25], renal failure, and obesity. The proposed
mechanism by which ischaemia results in ele-
vated BNP may be through up regulation of the
ventricular BNP expression or by transient in-
creases in left ventricular wall stress [25,26]. The
LVEF most widely accepted as a threshold value
is >50%. Diastolic dysfunction refers to impaired
LV filling capacity due to abnormalities in
Figure 1. Diagram of normal left ventricular pressure–volume loop (left panel) and in diastolic dysfunction (right panel). The diastolic pressure
volume curve is displaced upward and to the left. The systolic function of the LV is unchanged.
Table 1. The European Society of Cardiology Criteria for
Diastolic Heart Failure [29].
The European consensus criteria for diastolic HF
1. Signs and symptoms of CHF
Effort dyspnoea, orthopnea, pulmonary rales/oedema.
Cardiopulmonary exercise testing (VO2 max
< 25 ml/kg/min)
2. Normal or mildly reduced ejection fraction and
normal chamber size
LVEF > 50% and
Normal LV end diastolic volume(<97 mL/m2)
3. Abnormal LV relaxation, filling or diastolic
distensibility or stiffness
Echocardiographic: Tissue Doppler (E/Ea > 15)
LA volume P34 ml/m2 if E/Ea between 9 and 14
Cardiac catheterisation: LVEDP > 16 mmHg
Biomarkers NT-proBNP > 220 pg/ml or BNP > 200 pg/
ml
All three criteria are required for the diagnosis of diastolic heart failure.
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DIASTOLIC DYSFUNCTION AND HEART FAILURErelaxation or stiffness of the myocardium. This is
characterized by the upward and leftward dis-
placement of the end-diastolic pressure volume
relationship (Fig. 1). However, these changes
may occur in patients with diminished systolic
function and in the absence of overt HF, and
hence by themselves do not confirm a diagnosis
of HFpreEF. The need for confirming evidence of
diastolic dysfunction remains controversial partic-
ularly if there is evidence of hypertrophic remod-
eling [27,28]. Zile et al. examined 63 patients with a
history of HF and an echocardiogram suggesting
LV hypertrophy and a normal ejection fraction
[28]. Ninety-two percent of these patients had
some abnormality in LV relaxation, filling or dia-
stolic stiffness. The updated consensus statement
from the European Society of Cardiology is sum-
marised in Table 1. This report considers an LV
wall index >122 g/m2 or an LV wall mass index
>149 g/m2, in the presence of symptoms, adequate
evidence for the diagnosis of diastolic HF when
other modalities such as Tissue Doppler Imaging
(TDI) are inconclusive in the context of elevated
BNP levels [29].
Pathophysiology
The four phases of diastolic function are de-
picted in Fig. 2. The optimal LV pressure curve
would be rectangular allowing the maximal time
for ventricular filling [30]. The structural, func-
tional and molecular mechanisms involved in dia-
stolic dysfunction can conceptually be divided in
those that occur at the cardiomyocyte level and
those that are extrinsic to the myocyte [28,29].Cardiomyocyte
At the myocyte level, changes in calcium
homeostasis result in an increased diastolic cyto-
solic calcium. This may be as a result of (1) abnor-
malities in the sarcoplasmic reticulum calcium (SR
Ca2+) reuptake due to decreases in SR Ca2+ ATP-
ase (2) abnormalities in the ionic channels respon-
sible for calcium transport, and (3) changes in the
state of phosphorylation of proteins such as phos-
pholamban, calmodulin and calsequestrin that
modify SR Ca2+ ATPase function [31,32]. Increased
cytosolic calcium causes abnormalities in both ac-
tive relaxation and passive stiffness [33].
Figure 2. The four phases of diastole. The first point of intersection marks the end of the isovolumic relaxation (IR) phase and mitral valve
opening. In the rapid filling phase the left atrial (LA) pressure is higher than the left ventricular (LV) pressure. The second pont of intersection LV
pressure exceeds LA pressure resulting in decelerating flow. During the slow filling phase there is almost no pressure difference between the two
chambers. Atrial contraction raises the LA pressure above the LV pressure. The period between the first two intersection points corresponds to the
E wave seen on transmitral flow.
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dial relaxation is an active process and ATP
hydrolysis is required for actin-myosin separa-
tion, calcium dissociation from Tn-C and calcium
sequestration by the SR [34]. The sensitivity of
the myofilament to calcium has recently been re-
viewed by Kass et al. [35]. Current evidence sup-
ports a modified theory of excitation–contraction
coupling that myosin cross bridges binds weakly
to the actin filament in the relaxed state and cre-
ates a closed state [36]. In this closed state the
cross-bridging interaction creates a non-force gen-
erating reaction [37] Troponin I is necessary to
tether the actin and maintain diastole. Altered tro-
ponin I function can produce diastolic dysfunction
[38].
Data from explanted hearts and other models of
HF show a shift towards higher intracellular Na+
[39–43]. The consequence of this high [Na+]i is
cytosolic Ca2+ overload and alterations in cell
growth and metabolism, which in turn result in
selective abnormalities in diastolic function [39–
43].
Abnormalities in myocardial phosphate metab-
olism also influence diastolic function. Normal
diastolic function requires that the concentration
of the products of ATP hydrolysis, ADP and inor-
ganic phosphate [Pi], must remain low and pro-
duce the appropriate relative ADP/ATP ratio
[23,44–47]. Diastolic dysfunction may occur if the
absolute concentration of ADP increases or the
[48] phosphocreatine/ATP ratio decreases. Studies
in isolated heart models have also demonstrated
diastolic dysfunction coupled to metabolic inhibi-tion or ischaemia linked to increased free ADP
[49].
The cardiomyocyte cytoskeleton is composed of
microtubules, intermediate filaments (desmin),
microfilaments and endosarcomeric proteins (ti-
tin, nebulin, alpha-actin, myomesin and M-pro-
tein) [50]. Changes in the cytoskeleton proteins
may alter diastolic function [51–53]. The sarco-
meric macromolecule titin has been recognized
as a major determinant of both viscoelastic stiff-
ness and relaxation [54]. Titins span the entire sar-
comere extending from the Z-line to the centre of
the sarcomere [55]. During contraction, potential
energy is gained when titin is compressed. During
diastole, titin acts like a spring and expends this
potential energy, providing a recoiling force to re-
store the myocardium to its resting length [55,56].
Titin also protects the myocardium from being
stretched beyond the resting length [52,55]. Titin
is expressed in two isoforms: a smaller, stiffer
N2B and a larger, more compliant N2BA. The ratio
of N2BA to N2B is reduced in DHF [55,57]. The
mechanisms involved in isoform switching are
poorly understood but probably relate to chronic
pressure overloading [55,57]. Pressure overload
may increase microtubule density and distribu-
tion and increase myocardial stiffness.
A seminal paper by Selby et al. was amongst the
first to use a LV biopsy sample obtained during
coronary artery bypass surgery to examine tachy-
cardia-induced relaxation abnormalities in pa-
tients with a normal ejection fraction [58]. Tissue
samples obtained from patients with left ventricu-
lar hypertrophy (LVH) had some evidence of
Table 2. Studies comparing systolic and diastolic heart failure (na = not available from published data, NS = not significant).
Author Year EF (%) Number of
patients (%DHF)
Follow up Mean age (years ± SD) Mortality (%) P value
SHF DHF SHF DHF
Smith [105] 2003 40 413 (48%) 6 months 70 ± 11 73 ± 11 21 13 0.02
Vasan [8] 1999 50 73 (51%) 5 yr 74 ± 7 72 ± 9 64 32 0.02
Cohn [106] 1990 45 623 (13%) 1 yr 58 ± 8 60 ± 7 19 8 0.0001
Ansari [108] 2003 45 147 (44%) 22 months 69 ± 11 66 ± 11 12 8 NS
Senni [258] 1998 50 59 (43%) 1 yr 74 ± 12 78 ± 12 42 56 NS
5y 84 85 NS
Bhatia [109] 2006 50 2802 (30%) 1 yr 72 ± 12 75 ± 12 25 22 0.07
Table 3. Criteria used to define diastolic dysfunction (modified from Nageuh et al. [30] and Gabriel et al. [259].
Criteria Normal adult Impaired
relaxation
(stage 1)
Pseudonormal (stage 2) Reversible
restrictive (stage 3)
Irreversible restrictive
(stage 4)
E/A ratio 1–2 <1 1–1.5 (reverses with
Valsalva maneuver
>1.5 1.5–2 (no change with
Valsalva maneuver)
Deceleration
time (ms)
150–240 >240 150–200 <150 <150
IVRT (ms) 70–90 >90 <90 <70 <70
PV S/D ratio >1 >1 <1 <1 <1
PV Arev-MV A
wave (ms)
<0 <0 or >30 >30 >30 >30
Arev velocity
(cm2)
<35 <35 >35 >35 >35
Vp >55 >45 <45 <45 <45
E0 velocity >8 <8 <8 <8 <8
LA volume
index
<34 ml/m2 <34 ml/m2 >34 ml/m2 >34 ml/m2 >34 ml/m2
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DIASTOLIC DYSFUNCTION AND HEART FAILUREincomplete relaxation when paced a baseline of
60 beats/min that worsened when paced at 180
beats/min. The myocardial tissue samples from
patients without LVH did not exhibit any evidence
of relaxation abnormalities at baseline or 180
beats/min. The study also found a mechanistic
explanation for this observation. In the LVH group
they observed a higher resting tone, abnormalities
in calcium actin-myosin cross bridge activation,
and abnormalities in sarcolemmal calcium–so-
dium exchange with an increased cellular calcium
load. Tachycardia is common during critical ill-
ness and in the perioperative period and this
study helps explain the effects of tachycardia in-
duced diastolic dysfunction.
Extracellular matrix
The myocardial extracellular matrix is a dynamic
tissue that responds to environmental cues and
tissue injury [59]. It is comprised of (1) fibrillar
proteins such as collagen type 1, collagen type III
and elastin; (2) proteoglycans and (3) basement
proteins such as collagen type IV, laminin and
fibronection. Changes in fibrillar collagen may
be responsible for the development of diastolicdysfunction and diastolic HF [60–62]. Collagen
homeostasis has three major determinants: tran-
scriptional regulation, post-transcriptional regula-
tion and enzymatic degradation [63]. Loading
conditions, neurohormonal activation and growth
factors influence collagen synthesis. Enzymes that
influence collagen degradation include the colla-
genases, the matrix metalloproteinases (MMPs)
and tissue inhibitors of MMPs (TIMPs) [64,65].
Alterations in the activity of these enzymes may
result in left ventricular remodeling [64]. Inhibi-
tion of MMPs may result in increased myocardial
collagen with increased LV stiffness. Increased
MMPs activity results in a 2-tiered response. Ini-
tially the myocytes respond to increased collagen
destruction by myocardial hypertrophy and in-
creased collagen production. Over a period of
time, there is a decreased rate of pressure decre-
ment during diastole [66]. Elevations of collagen
turnover occur in patients with asymptomatic dia-
stolic dysfunction as well as diastolic HF [67]. In
addition, the magnitude of collagen turnover cor-
relates directly with the severity of diastolic dys-
function [67]. There are four subtypes of TIMP in
the normal myocardium [68,69]. The profile of
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in myocardial ischaemia. TIMP-4 is upregulated
in hypertension. A deficiency in TIMP-3 may be
directly related to cardiac remodeling and the evo-
lution of HF [70]. The specific contribution that
TIMP makes to diastolic dysfunction is unresolved
and a better understanding of this complex pro-
tein in HF is warranted.Age related changes in diastolic function
During aging, changes related to increased myo-
cardial and ventricular stiffening and diminished
b-adrenergic receptor responsiveness are highly
significant. At the myocyte level, age-related
reductions in SERCA2 levels and activity result
in abnormal diastolic sequestration of calcium
[71–74]. An increase in activity of phospholamban
also impairs diastolic function. Aging is associated
with a b-adrenergic associated signal dampening
[75,76]. This may be due to receptor down-regula-
tion or due to reduced receptor coupling to adenyl
cyclase via Gs proteins. There is some evidence
that the adrenergic receptor density changes with
age with a decrease in high affinity b-receptor
[77,78]. There is also an age related increase in
myocyte size but decrease in myocyte number
[79]. At the extracellular matrix level there is an
age-related interstitial fibrosis as a result of in-
creases in fibrin, fibronectin and collagen. Age re-
lated degeneration of the conducting system
makes elderly patients prone to arrhythmia and
further compromises diastolic function [80]. Aging
is associated with systolic-ventricular and arterial
stiffening [81–84], which may influence diastolic
function in several ways. Arterial stiffening in-
creases myocardial oxygen consumption for a gi-
ven stroke volume and ventricular systolic
stiffening exacerbates this effect. Energy costs
are predicted to be >50% higher in patients with
HfpreEF than controls [85]. The increased arterial
stiffness results in ventricular hypertrophy to pre-
serve systolic function at the expense of left ven-
tricular compliance and filling [84,86].Assessment of diastolic function
Echocardiography
The ideal method to assess diastolic function
should be widely available, easy to interpret and
accurate. Unfortunately this remains elusive and
all existing methods have limitations. Invasive
techniques have largely been replaced by echo-
cardiography. The reference ranges for the echo-
cardiography variables used have been derivedfrom studies employing transthoracic echocardi-
ography (TTE). However in the perioperative
and critical care context TTE is often technically
challenging. This may be due to difficulties with
patient positioning, or a reduction of the acoustic
window by high levels of positive end expiratory
pressure, the presence of injuries, drains or
dressings on the precordial area [87,88]. Trans-
esophageal echocardiography (TEE) has been rec-
ommended to overcome these limitations [89].
The reference ranges are derived from awake pa-
tients undergoing TTE in the lateral decubitus po-
sition. This is in contrast to the supine
anaethetised patient receiving mechanical ventila-
tion under dynamic haemodynamic conditions
influenced by anaesthetic drugs [90–93]. A com-
prehensive review on the perioperative assess-
ment of diastolic function has recently been
published and the reader is referred here [93]. A
summary of the criteria commonly used to define
diastolic dysfunction is presented in Table 3 [30].
The mitral inflow velocity is one of the early
echocardiographic indices used to define diastolic
dysfunction. Early transmitral inflow is denoted as
E velocity and depends on left atrial compliance,
left ventricle compliance, the rate of left ventricle
relaxation and the suction effect created by the
base to apex intraventricular pressure gradient at-
rial contraction is represented by the A velocity
and is influenced by left atrial contractility and left
ventricular compliance. The deceleration time
(DT) is the time interval between the peak of the
E wave to baseline and represents the time for
equalization of pressure between the left atrium
and ventricle (Fig. 2). While mitral inflow veloci-
ties are easily obtained, they are highly preload
dependant and problematic in patients with atrial
fibrillation. Diastolic dysfunction results in de-
layed transfer of blood from atrium to ventricle.
The atrium responds by emptying more vigor-
ously and soon accounts for the dominant compo-
nent of left ventricular filling. In response to
chronic increased left atrial impedance, the atrium
undergoes enlargement. As diastolic dysfunction
evolves further the atrial pressure increases and
the DT decreases, the E/A ratio and the DT appear
normal (grade II). With further deterioration of
diastolic function the E/A ratio may exceed 2 and
the DT < 150 ms. Haemodynamic manipulation
such as the Valsalva maneuver will distinguish
between severe irreversible diastolic dysfunction
(grade IV) from less severe reversible (grade III)
disease.
The pulmonary vein has a systolic (S wave), a
diastolic (D wave) and an atrial reversal (Arev
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DIASTOLIC DYSFUNCTION AND HEART FAILUREwave) component (Fig. 2). These waves are reci-
procal to the left atrial waves. The S wave can be
divided into S1 and S2. The S1 occurs during LA
pressure ‘‘a’’ to ‘‘c’’ and ‘‘c’’ to ‘‘x’’ descent, and
the S2 occurs during LA pressure increase be-
tween the ‘‘x’’ pressure nadir and the ‘‘v’’ pres-
sure peak [94,95]. The D wave correlates with the
mitral E wave velocity. The Arev is determined
by atrial and ventricular compliance and atrial
contractility. The isovolumic relaxation time
(IVRT) is the time interval between the aortic
valve closure and mitral valve opening. The IVRT
is normally 70–90 ms and is influenced by heart
rate and loading conditions. Trends may be more
helpful than absolute values.
The mitral inflow propagation velocity (Vp) is
measured using colour M-Mode. This provides
velocity information along a scan line that extends
from the mitral valve to the LV apex.
Refinements in echocardiography technology
include Tissue Doppler Imaging (TDI), colour
TDI, strain and strain rate and have become an
important part of clinical practice [96].
Conventional echocardiography filters out low
velocity, high amplitude signals and derives the
velocity and flow of blood by measuring the
Doppler shifted frequency of the low amplitude,
high frequency signal returning from blood flow.
TDI excludes the signal from blood flow and
interrogates the signal from myocardial tissue.
Three waveforms are noted- S (systolic), Ea (early
diastolic), and Aa (late diastolic). Colour TDI
measures the mean velocities whereas pulse
wave Doppler measure peak velocities in the
sample volume [96–99]. TDI has two important
limitations. Firstly, the measured velocities are
dependent on the angle of insonation. Secondly
TDI is of limited utility in analyzing regional wall
motion abnormalities as TDI cannot differentiate
actively contracting myocardium from infarcted
myocardium that is tethering. Strain and strain
rate is derived from colour TDI. Strain is the
measure of myocardial deformation and is the
change of length (L) of a myocardial segment ref-
erenced to its original length (L0) as given by the
equation E = L  L0/L0 [100]. If both LO and L are
known then this referred to Lagrangian strain.
Natural strain refers to when the L is referenced
not to the original length but to the length at the
preceding time interval [101]. TDE measures nat-
ural strain and magnetic resonance imaging mea-
sures Lagrangian strain. Strain rate is the rate of
myocardial deformation and is expressed as
change of strain per unit time. A more recent
innovation to strain analysis is speckle tracking[102]. This involves a computer algorithm using
routine greyscale imaging that contain unique
speckle patterns. Within a user-defined area on
the myocardial wall, the image processing algo-
rithm to track frame by frame changes in the
speckle pattern to velocity vectors [103]. These
advances have well described in recent publica-
tions and are beyond the scope of this review
[89,93,96,102].Prognosis
There is a clear association between diastolic
HF, asymptomatic diastolic dysfunction, and mor-
tality that is influenced by several variables,
including the population being studied, the
threshold EF used to define DHF and the influ-
ence of co-morbidities. Several variables have
been identified as independent clinical predictors
of mortality in patients with HF. These include
age, New York Heart Association Class IV symp-
toms, CAD, Diabetes, peripheral vascular disease
and the presence of valvular heart disease.
Whether patients survive longer after a diagnosis
of systolic HF than a diagnosis of systolic HF is still
debated [104–109] (Table 2). Hospital readmission
rates and length of hospital stay for patients with
HFpreEF are similar to SHF and the former have
a higher likelihood of functional limitations or la-
bile symptoms on follow-up [110,111]. When out-
come from HF is adjusted for the contribution of
co-morbidity, there is a uniformly poor prognosis
regardless of the ejection fraction.
Information regarding the prognosis in asymp-
tomatic diastolic dysfunction is sparse. A commu-
nity based study of 2042 patients 45 years and
older found that patients with diastolic dysfunc-
tion without a history of cardiac failure have a sig-
nificant risk of death [112]. Compared with normal
diastolic function, those with mild diastolic dys-
function have a hazard ratio of 8.31 (p < 0.001,
95% CI 3.00–23.10) and those patients with moder-
ate to severe diastolic dysfunction have a hazard
ration of 10.17 (p < 0.001 95% CI 3.28–31.00) for
5 year mortality [112]. This observation has been
confirmed by other reports [9113]. Wang et al. per-
formed one of the earliest studies evaluating the
relationship between TDI-derived mitral annular
velocities and outcome [114]. A total of 518 pa-
tients were recruited for this study (353 with car-
diac disease and 165 normal subjects) with the
endpoint of mortality at 2 years. This study found
that if the Ea or S peak velocities were between 3
and 5 cm/s then the hazard ratio for death was
12.8 (95% CI 2.9–56) [114].
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Pre-operative assessment
The American College of Cardiology and the
American Heart association (ACC/AHA) as well
as the European Society of Cardiology and
European Society of Anesthesiology (ESC/ESA)
guidelines recommend the use of risk indices for
pre-operative cardiac evaluation for non-cardiac
surgery [115,116]. The Goldman, Detsky and Re-
vised Cardiac Risk Index (RCRI) all identify HF
as a predictor of perioperative cardiovascular
events [117–119]. A limitation of these risk indices
is that they do not account for the patient with
decompensated HF who improves both symptom-
atically and functionally on medical therapy.
When this patient presents for elective surgery
several months later, the patient’s perioperative
risk calculated by the original Goldman Index does
not appreciate the history of HFHF and the RCRI
does not appreciate the patient’s clinical improve-
ment. There is no specific risk model for predicting
perioperative risk in patients with HfpreEF.
When planning surgical procedures in patients
with stable HF, it is important to identify those pa-
tients that are unlikely to survive long enough to
accrue benefit from the procedure. Data from stud-
ies describing the clinical profile of cardiac trans-
plant patients have highlighted the difficulties in
predicting survival in patients with advanced HF.
Several prognostic models have been developed
to identify those patients with advanced HF with
a high risk of death needing urgent transplanta-
tion. These include the Heart Failure Survival
Score (HFSS), the Seattle Heart Failure Model
[120], and more recently the MUSIC Risk Score
[121,122]. None of these scores were specifically in-
tended for pre-operative risk stratification, but
may offer some guidance in making difficult deci-
sions in patients with HF that may require surgery.
There is limited data on perioperative risk strat-
ification for isolated diastolic dysfunction. Patients
requiring vascular surgery have been shown to
frequently have asymptomatic isolated diastolic
dysfunction that is associated with a significantly
higher rate of major adverse cardiovascular events
(MACE). The study by Flu and colleagues found
about 50% of vascular surgical patients to have
isolated diastolic dysfunction and 80% of these pa-
tients were asymptomatic. The study found an OR
2.3 (95% CI 1.4–3.6) for 30 day MACE in all pa-
tients with diastolic dysfunction compared with
no ventricular abnormalities, abnormalities. The
OR for MACE in symptomatic HF was 1.8 (95%
CI 1.1–2.9). This study highlights the importanceof looking beyond HF symptoms and advocates
for the use of echocardiography in patients under-
going high-risk surgery. A similar study by Matyal
and colleagues found 43% of patients to have iso-
lated diastolic dysfunction and a strong associa-
tion in these patients with a prolonged length of
stay and higher rates of post-operative HF. Inter-
estingly the study did not find an association with
perioperative outcomes and systolic dysfunction.
The association was between isolated diastolic
dysfunction and perioperative MACE in cardiac
surgical patients. Isolated diastolic dysfunction
has been shown to increase the risk for postoper-
ative atrial fibrillation in cardiac surgical patients
[123]. These observations make a compelling case
for the routine assessment of peroperative dia-
stolic function.Exercise capacity and diastolic dysfunction
Exercise capacity is a useful pre-operative
screening test. A self-reported limitation in exer-
cise capacity has a negative predictive value of
95% and a positive predictive value of about 10%
for a major perioperative cardiovascular event
[124,125]. Exercise intolerance is often the earliest
clinical presentation of diastolic dysfunction and
is a major determinant of quality of life [126].
Recent evidence suggests diastolic dysfunction
may impair the Starling mechanism during exer-
cise [127,128]. The tachycardia that occurs during
exercise reduces ventricular filling time. In
healthy individuals ventricular filling is main-
tained by progressive acceleration of the IVRT
and an increased suction effect by a more rapid
fall in early diastolic LV pressure [129]. In patients
with diastolic dysfunction this compensatory
mechanism fails [129]. These patients are unable
to augment their cardiac output by increasing
their end diastolic volume. Left ventricular end
diastolic pressure and pulmonary venous pres-
sure rises, reducing the pulmonary compliance
and increasing the work of breathing [129].
Patients with diastolic dysfunction have an asso-
ciated reduction in chronotropic, vasodilator and
cardiac output reserve compared with patients
without diastolic dysfunction [123,130]. It is thought
that these factors may also contribute significantly
to the observed limitations in functional capacity.Implications in the perioperative period
Asymptomatic diastolic dysfunction is fre-
quently underappreciated in the elderly surgical
population. Phillip et al. conducted a prospective
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for cardiac disease determining the prevalence of
diastolic dysfunction in the geriatric surgical pa-
tient. [131]. The mean age of the patients was
72 ± 7 years and diastolic filling abnormalities
were discovered in 61.5% of the patients. A major
limitation of this study was that no outcome mea-
surement was performed so the clinical signifi-
cance of the findings was not established.
Similarly observations have been reported in pa-
tients undergoing elective vascular surgery [132].
It is highly likely that elderly patients with vascu-
lar disease or hypertension would have some de-
gree of diastolic dysfunction.
Induction of anaesthesia results in significant
alterations in ventricular filling in patients with
diastolic dysfunction [133]. This may be due to
positive pressure ventilation, reduced venous
return and reduced right atrial contractility. In
patients having aortic surgery, application of
the aortic cross clamp worsens diastolic perfor-
mance that returns to baseline upon release of
the cross clamp [134]. In patients requiring car-
diac surgery, diastolic dysfunction has been
shown to be a better predictor of haemody-
namic instability than systolic dysfunction
[135,136]. Moderate and severe diastolic dys-
function is also independently associated with
difficulties with separation from cardiopulmo-
nary bypass [135,137]. Pre-operative diastolic
dysfunction is associated with a range of ad-
verse outcomes including higher mortality,
worse mitral regurgitation and longer hospital
stay in patients requiring surgical ventricular
restoration, mitral valve annuloplasty or elective
vascular surgery [132,138,139].
Perioperative atrial fibrillation in patients with
diastolic dysfunction results in a significant reduc-
tion in left ventricular filling and cardiac output
due to loss of atrial kick. Atrial fibrillation may
be precipitated by hypovolaemia, hypervolaemia
with atrial overdistension, electrolyte abnormali-
ties, particularly hyper and hypokalaemia, anae-
mia, abrupt withdrawal of beta-blockers or
calcium channel blockers, and ischaemia. The on-
set of atrial fibrillation has been shown to precip-
itate HF in patients with pre-existing diastolic
dysfunction [140]. The presence of pre-operative
diastolic dysfunction is a strong independent
predictor for developing post-operative atrial
fibrillation after cardiac surgery [141]. Diastolic
dysfunction also predicts long term rhythm after
intraoperative ablation for atrial fibrillation [142].
The dominant mechanism is probably inflamma-
tory mediated though the exact etiology for thedevelopment of atrial fibrillation in these patients
is unknown. This may explain the observation that
statins may reduce the rate of atrial fibrillation
after cardiac surgery [143].
Myocardial ischaemia results in significant
impairment in LV relaxation and increases the
risk of rhythm disturbances as already discussed.
The earliest abnormality induced by epicardial
occlusion is a reduced ventricular compliance.
This precedes regional wall motion abnormalities,
electrocardiographic changes or chest pain [144].
There are two mechanism by which acute myocar-
dial ischaemia induces diastolic dysfunction [145]
The first mechanism is by arterial hypoxaemia
and occurs within 2 min, The second mechanism
is by perfusion ischaemia and occurs at about
20–30 min. Diastolic dysfunction is commonly
associated with LVH. Increases in intra-cavitary
pressure together with increased left ventricular
mass result in malperfusion of the left ventricle.
LVH may be eccentric or concentric. Each geomet-
ric pattern is associated with a particular pressure
or volume stimuli, contractile efficiency and prog-
nosis. The concentric pattern carries the worse
prognosis compared with eccentric hypertrophy
[146]. In patients with right HF, increased right
atrial pressure impairs postcapillary blood flow
resulting in coronary venous engorgement [33].
Right ventricular dilatation may also impede LV
filling by ventricular interdependence.
There is limited clinical data on the effect of
anaesthetic drugs on diastolic function. The choice
of anaesthetic technique has been shown to influ-
ence diastolic properties in patients with pre-
existing diastolic dysfunction [91,147]. In a small
randomised study of 24 patients, the use of sevo-
flurane during spontaneous ventilation preserved
early diastolic function better than propofol. How-
ever during a balanced anaesthetic technique with
positive pressure ventilation, no difference be-
tween sevoflurane and propofol on diastolic func-
tion was observed [91]. These findings are
consistent with other studies [147]. The mecha-
nism by which propofol affects diastolic function
are similar to volatile anaesthesia [148,149]. There
is impaired calcium reuptake by the sarcoplasmic
reticulum and modulation of phosphorylation of
the contractile proteins [150]. More recently a
comparisons between isoflurane, desflurane and
sevoflurane found no significant effect on diastolic
performance in healthy subjects and no difference
between these agents in patients with diastolic
dysfunction [151]. Morphine and midazolam do
not appear to have any effect on diastolic perfor-
mance [152,153]. Similarly, remifentanil has been
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healthy volunteers [154].Diastolic dysfunction and sepsis
The occurrence of myocardial dysfunction in pa-
tients with sepsis carries a significant burden of
mortality (70%) compared with those patients that
do not have myocardial dysfunction [155]. Both
systolic and diastolic dysfunction have been de-
scribed. Parker et al. demonstrated the relation-
ship between diastolic dysfunction and sepsis in
1984 [156] comparing haemodynamic and radio-
nuclide cineangiographic data between a group
of 20 patients with septic shock and a control
group of 32 critically ill patients with negative
blood cultures, not in shock. The patents with sep-
tic shock were volume resuscitated to a PAWP of
12–15 mmHg and inotropes were added as re-
quired. Survivors of septic shock (n = 13) had high
left ventricular volumes (mean left ventricular end
diastolic volume index (LVEVPI) 159 ± 29 mL/m2)
that returned to normal by about 10 days. Non-
survivors had normal mean LV volumes (mean
LVEDVI 81 ± 9 mL/m2) that did not change during
the 10 day period. Unfortunately, no ventricular
volume data was reported for the control group.
The same group of investigators evaluated 39 pa-
tients with septic shock again using haemody-
namic and radionuclide angiographic studies
[157]. Survivors (n = 22) displayed simultaneous
biventricular dilatation that returned to normal
after recovery. Non-survivors (n = 17) displayed
less severe dilatation but did not improve on sub-
sequent evaluation. Changes in right ventricular
volumes paralleled changes in the left ventricle
[157].
Using both haemodynamic and radionuclide
measurements, in a group of 56 patients admitted
to ICU, Ognibene et al. was able to show higher
PAWP with a trend towards higher LVEDVI in pa-
tients with septic shock compared with controls
[158]. The pre-enrollment fluid resuscitation in
the septic shock group was more aggressive than
the controls making the data difficult to interpret.
More recent studies have used echocardiogra-
phy to evaluate diastolic performance. Jafri et al.
observed that Doppler parameters of LV filling
were abnormal in a subset of 46 septic patients
with or without shock [159]. The clinical signifi-
cance of the study is unclear as there was a statis-
tically significant difference in the heart rate
between the control group and the sepsis group
(116 ± 15 beat/min septic shock, 110 ± 26 beat/
min, sepsis without shock vs. 73 ± 12 beat/mincontrols, p < 0.05) and the echocardiography
modality used does not account for patients with
pseudonormal filling pattern. Subsequently, Munt
et al., have demonstrated similar abnormalities in
diastolic performance in a group of 24 critically ill
patients [160]. This report also identified abnor-
malities of LV filling as being independently pre-
dictive of mortality [160]. Non-survivors of
severe sepsis had more abnormal Doppler param-
eters of diastolic relaxation, as measured by E/VTI
and deceleration time (DT). In a multivariate anal-
ysis, DT was the only echocardiographic parame-
ter that independently predicted mortality. All
patients were studied within 24 h of presentation
and after volume resuscitation. There was no
difference in mean pulmonary artery occlusion
pressure or heart rate between survivors and
non-survivors. This study has several limitations
that deserve comment. Although patients with
pre-existing cardiac disease were excluded, there
was no control group and systolic function was
not assessed making it difficult to draw meaning-
ful conclusions. Mortality was significantly associ-
ated with advanced age and also with abnormal
Doppler parameters of diastolic relaxation. It is
impossible to determine whether sepsis induced
an abnormality of LV relaxation in non-survivors,
or whether there was pre-existing diastolic
dysfunction in this subgroup of patients. Interest-
ingly, cardiac output was actually higher in non-
survivors than in survivors in this study [160].
Baitugaeva et al. examined diastolic perfor-
mance in 59 patients between the ages of 18–
24 years with sepsis, severe sepsis and septic
shock and noted a significant relationship be-
tween diastolic dysfunction and pro-inflammatory
cytokines [161]. The patients in this age group are
unlikely to have pre-existing diastolic dysfunction.
The findings in these studies are consistent with a
growing body of evidence from experimental
studies that supports the concept of sepsis or
endotoxin induced abnormalities in LV compli-
ance [162,163]. The majority of these studies have
shown a reduction of ventricular compliance by
pressure–volume analysis early (within hours)
into the course of sepsis without ventricular dila-
tion. Over a period of days and with the adminis-
tration of intravascular volume, the left ventricle
dilates. Measured compliance at this stage may
still be reduced, or may return toward normal,
and it has been proposed that ventricular compli-
ance in sepsis may be volume dependent [2]. It is
estimated that about 20% of patients with septic
shock will have some impairment of left ventricu-
lar relaxation [164]. The spectrum of cardiac
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abnormalities to HFpreEF and systolic HF.
Ventricular dilation seen in early studies in both
human and animal studies has been implicated in
the maintenance of cardiac output in the face of
impaired contractility [165].
Animal models have confirmed both systolic
and diastolic dysexplored the differential ability
of inotropes to restore diastolic function
[166,167]. Dobutamine improved systolic function
but did not improve diastolic dysfunction in ani-
mal models of sepsis.
There are several confounding issues that make
evaluation of diastolic performance in critical ill-
ness particularly challenging. These include the
potential effects of inotropes, volume resuscitation
and the lack of well-established reference ranges
for diastolic parameters in critical illness. It is
hoped that the use of more standardised methods
for evaluating diastolic function such as TDI and
strain rate will overcome some of these difficulties
and provide insight into the interrelation of sepsis
and ventricular diastolic function and its implica-
tions for patient survival.Pediatric patients with cardiac disease
It is important to understand the maturation of
diastolic function before we can appreciate dia-
stolic dysfunction in the pediatric patient. Data
from 238 healthy neonates suggests that at birth
there is impaired left ventricular relaxation char-
acterized by a prolonged isovolumic relaxation
time and limited early diastolic filling predomi-
nantly dependant on atrial contraction [168]. In
the first week of life there are improvements in left
ventricular relaxation. By two months of age the
pattern of transmitral flow changes dramatically
with early mitral flow velocities increasing by
about 80% from newborn values [168,169]. The ef-
fect of heart rate on early filling appears to be neg-
ligible and does not account for the observed
differences [168]. In contrast, during the same per-
iod, there are no significant improvements in tri-
cuspid diastolic annular motion or inflow
velocities, implying that the right ventricle has de-
layed improvement in diastolic function [169]. In
pre-term infants the maturation of diastolic func-
tion is prolonged and at two months there is still
a predominance of diastolic filling during atrial
contraction [170]. The maturational process of dia-
stolic performance takes about three months and
limits tolerance to preload stressors [171]. A study
of cardiac growth in healthy children using TDI
showed a correlation between diastolic function
and age [172].In children with congenital heart disease, dia-
stolic dysfunction has historically been under-
recognised. The use of transcatheter techniques
have advanced the understanding of diastolic dys-
function in children. TDI and strain rate and strain
imaging studies have revealed no significant in-
crease in left sided pressure after closure of an at-
rial septal defect (ASD) [173–176]. In contrast, ASD
closure in adult patients is characterised by an in-
crease in left ventricular dimensions, elevations in
N-terminal proBNP, delayed improvement in
exercise tolerance and even HF [177]. This makes
a convincing case for early closure of ASD [178].
Following repair of a patient with Tetralogy of
Fallot (TOF), several acute and chronic complica-
tions have been shown to have a significant im-
pact on the post-operative course. In these
patients, biventricular systolic function is usually
well preserved with restrictive right ventricular
physiology [179]. Right ventricular restriction is
characterised by anterograde diastolic pulmonary
flow, implying that the right ventricle has become
a stiff conduit in late diastole [180–185]. Restrictive
filling following repair of a TOF is associated with
increased inotropic requirements, prolonged
mechanical ventilation time, higher doses of
diuretics and longer hospital stay as well as poor
exercise capacity and symptomatic arrhythmias
[182]. Recent studies using TDI and strain rate
and strain, after complete repair of TOF, have
found significant systolic and diastolic dysfunc-
tion of the right ventricle. These patients have a
significant risk of late right ventricular failure,
and pulmonary insufficiency [183–185]. TDI and
strain rate may provide invaluable information
about the need for pulmonary valve replacement.
These reports provide further evidence that com-
plete repair of TOF should be performed during
infancy as delayed repair exposes the myocar-
dium to chronic hypoxaemia and hypertrophy
[186,187].Diastolic dysfunction and medical disease
Renal disease
There appears to be a consistent relationship be-
tween diastolic dysfunction and chronic renal dis-
ease in both paediatric and adult patients [188].
There are two parallel pathophysiological mecha-
nisms that underlie the development of diastolic
dysfunction in patients with chronic renal insuffi-
ciency [188]. The first is that cardiac remodeling
results in left ventricular hypertrophy (LVH).
Pressure overload results in concentric LVH
whereas eccentric LVH may be related to volume
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tion phase of LVH results in decreased capillary
density, coronary reserve and subendocardial per-
fusion. Myocardial fibrosis with systolic and dia-
stolic dysfunction result.
The second mechanism involves vascular injury.
Chronic renal disease and cardiac disease share
many common risk factors. These include athero-
sclerosis and vascular calcification.
Chronic renal dysfunction is frequently associ-
ated with diastolic HF and has been shown to
independently increase mortality [189–194].
Ahmed and colleagues conducted a post hoc pro-
pensity-matched study of patients in the Digoxin
Investigation Group (DIG) trial to determine the
impact of LVEF, chronic renal insufficiency (CRI)
and mortality in a cohort of 7788 ambulatory pa-
tients in sinus rhythm [195]. DHF was present in
988 patients (defined as LVEF > 45%). Interest-
ingly, this study concluded that mortality associ-
ated with chronic renal insufficiency (CRI) was
higher in patients with diastolic HF compared
with SHF [195,196]. Additionally, there was a
graded relationship with higher CRI-associated
mortality occurring with increasing LVEF. There
are several potential explanations for this observa-
tion. The mean age of patients with DHF was
3 years older than patients with systolic HF
(P < 0.0001) and there were more patients
>75 years of age with CRI and DHF than systolic
HF. Renal impairment in DHF may represent
intrinsic renal disease in advanced age. Thirdly,
the influence of medical therapies needs to be ex-
plored. Patients with DHF do not show the same
prognostic improvement when commenced on
medical therapy when compared with matched
patients with HF and low EF [197]. Lastly, there
may be unmeasured co-variables that may ac-
count for these observations.Diabetes
Although diabetes is a well recognized risk fac-
tor for the acceleration of ischaemic heart disease
and hypertension, the relationship between dia-
betes and cardiac disease independent of these
diseases is less well understood. Diabetic patients
without significant coronary artery disease may
develop features of abnormal LV relaxation with
normal systolic function [198–201]. The severity
of the diastolic dysfunction correlates indepen-
dently with the derangement in glycaemic control
as manifested by elevated glycosylated haemoglo-
bin [199–201]. A nationwide case control study
showed that diabetes was independently associ-
ated with idiopathic cardiomyopathy [202]. Thepathophysiological mechanisms that underly the
relationship between diabetes and diastolic dys-
function are probably mediated through the
microcirculation. Intra vascular ultrasound studies
have shown impaired coronary flow reserve in
both type 1 and type 2 diabetic patients [203,204].
A reduced coronary flow reserve indicates coro-
nary microvascular dysfunction, in the absence
of epicardial coronary stenosis [205]. This micro-
vascular dysfunction may lead to myocardial cell
injury, fibrosis or apoptosis [206]. Other possible
mechanisms of microcirculatory dysfunction in-
clude autonomic dysfunction, endothelial dys-
function and insulin resistance [207–209]. The
cellular mechanisms that underly diabetic dia-
stolic dysfunction are probably due to three char-
acteristic metabolic abnormalities that are
observed in diabetes [201]. These are (1) hyper-
glycaemia which generates reactive oxygen spe-
cies causing mitochondrial dysfunction (2.)
hyperinsulinaemia which promotes myocyte
hypertrophy and (3) elevations in non-esterified
fatty acids which are thought to induce insulin
resistance and myocardial apoptosis [210–215].
The clinical features of the cardiovascular changes
induced by both type 1 and type 2 diabetes are
similar [216–218].Chronic obstructive airways disease (COPD)
The cardiovascular consequences of COPD in-
clude impaired left ventricular filling, arterial stiff-
ness, cor pulmonale and chronic HF [219]. The
Multi Ethnic Study of Atherosclerosis (MESA)
Lung is a population based study that explored
the relationship between emphysema, airflow
obstruction and left ventricular filling in 2816 sub-
jects [220]. Magnetic resonance imaging was used
to measure left ventricular structure and function,
CT scanning was used to define the severity of
emphysema and spirometry was performed
according to the American Thoracic Society guide-
lines. The study found a linear relationship be-
tween both severity of emphysema and airflow
obstruction with impairment of left ventricular
filling, reduced stroke volume and cardiac output
without significant reductions in ejection fraction.
These findings are consistent with other work
which has highlighted the presence of both right
and left ventricular diastolic dysfunction early in
the course of COPD, without overt cardiovascular
disease [221]. The mechanisms by which COPD
causes impaired left ventricular filling include
pulmonary vascular changes, pulmonary hyperin-
flation, arteriolar hypoxia and ventricular interde-
pendence. Other less well understood
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Table 4. Summary of intravenous therapy for a hypertensive crisis [240,241].
Drug Class Dose Comments
Clevidipine Third generation dihydropyridine
CCB
Starting dose 1–2 mg/h, doubled
every 90 min until target BP reached.
No more than an average of 21 mg/hr
over a 24 h peiod
Specifically arteriole dilator. Rapid
onset 2–4 min. Agent contains
phospholipids that support microbial
growth and vial must be changed
every 4 h
Enalaprilat ACE inhibitor 1.25 mg every 6 h over a 5 min period.
50% dose reduction for patients with
creatinine clearance <30 ml/min
Onset of action 15–30 min. Peak effect
at 4hours and duration of effect 12–
24 h. Not easily titrated due to long
duration of effect
Fenoldopam Peripheral dopamine type 1 agonist Starting dose 0.1–0.3 lg/kg/min,
increased by increments of 0.05–
0.1 lg/kg/min every 15 min. Maxumin
rate 1.6 lg/kg/min
Onset of action within 5 min.
Duration of effect 30 min. Avoid in
patients with glaucoma, increased
ICP or sulphur allergy
Esmolol b1 adrenergic antagonist Loading dose 0.5–1.0 mg/kg over
1 min then 50 lg/kg/min infusion
increased by 50 lg/kg/min up to
maximum 300 lg/kg/min
Onset of action within 1 min.
Duration of effect 10–20 min.
Metabolized by erythrocyte esterases
Labetolol Combined a1 and non-selective b
adrenergic antagonist
20 mg iv bolus followed by 20–80 mg
iv bolus every 10 min or infusion 1–
2 mg/min
Duration of effect with infusion or
repeated bolus dose is 2–4 h
Sodium nitroprusside Nitric oxide donor Starting dose 0.3–05 lg/kg/min
increased by 0.5 lg/kg/min. avoid
dosed >2.0 lg/kg/min
Concern about cyanide, toxicity and
meth-haemaglobinaemia
CCB = calcium channel blocker, ACE = angiotensin-converting enzyme, ICP = intracranial pressure.
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dative stress, connective tissue degradation and
vascular dysfunction. Retrospective pharmaco-
epidemiologic studies have hinted at the possible
benefit of statins combined with low dose inhaled
corticosteroids at reducing the acute coronary
events and hospitalizations in patients with COPD
[222–224]. Randomized control trials are awaited.
Cirrhotic cardiomyopathy
The cardiac dysfunction noted in patients with
liver cirrhosis is greater than what is accounted
for based on alcohol alone and has been termed
cirrhotic cardiomyopathy [225]. The term refers
to spectrum of cardiac abnormalities that include
systolic and diastolic dysfunction, electrophysio-
logical changes such as prolonged QT interval
and a diminished response to catecholamines.
The mechanism by which cirrhosis causes dia-
stolic dysfunction is a combination of myocardial
hypertrophy, fibrosis and sub-endothelial oedema
[226]. Increased sodium intake may induce myo-
cardial hypertrophy and may in itself be responsi-
ble for some of the diastolic dysfunction observed
in these patients [227]. The severity of diastolic
dysfunction observed is more pronounced in pa-
tients with ascites. This may be a consequence of
the mechanical effects of ascites or reflect the
severity of liver cirrhosis [228]. Patients with dia-
stolic dysfunction are very sensitive to the volume
changes that occur with transjugular intrahepatic
portosystemic shunts (TIPS) procedures [229].
Portal decompression by TIPS results in rapid
shifts of larges blood volumes from the splanchnic
circulation to the heart. The persistence of dia-
stolic dysfunction after TIPS has been found to
be a strong independent predictor of mortality
[229]. Diastolic dysfunction has been associated
with a slower mobilisation of ascites [230]. Liver
transplantation improves/reverses diastolic dys-
function though the evidence is sparse [231]. The
time course for the changes that occur after trans-
plantation are not completely understood. Some
authors have reported a persistence of hyperdy-
namic circulation for up to two years after trans-
plantation and others report an immediate
amelioration to the cardiac and circulatory
disturbance.
Is diastolic heart failure a precursor to the
evolution of systolic heart failure or a syndrome on
its own?
Whether HF is a single syndrome with HFpreEF
preceding HF with systolic impairment or whether
HF is two distinct syndromes: one with concentricremodeling and diastolic dysfunction (DHF) and
the other with eccentric remodeling and systolic-
diastolic dysfunction (SHF) is unclear.
The evolution of our understanding of ventricu-
lar function had led to various models of cardio-
vascular performance each with its own set of
defining variables. If the myocardial performance
is defined as a haemodynamic pump then LVEF is
an important measure [55,218,232–234]. The hae-
modyamic performance of the heart is influenced
by factors outside the myocardium, such as pre-
load and afterload. LVEF is usually derived by ra-
dial measurements of the LV. During the early
period of systolic dysfunction, there may be radial
compensation for longitudinal impairment and
this does not reflect changes in regional and tem-
poral abnormalities in cardiac muscle
[232,233,235]. In this context, a normal ejection
fraction does not equate with preserved systolic
function. If myocardial performance is viewed as
a muscle pump then indices of longitudinal func-
tion and non-uniformity define ventricular perfor-
mance [55,232–235]. These include TDI derived
mitral annular velocity and strain and strain rate
and may reveal significant systolic impairment in
the face of a normal ejection fraction. Diastolic
and systolic HF may represent different pheno-
types of the same pathophysiological process
[55,232,233,235]. Proponents of the single-syn-
drome hypothesis suggest there is a progression
of disease from HfpreEF to HF with systolic
impairment and that the decline in systolic func-
tion may be better appreciated by tissue Doppler
indices than by LVEF [232,233,235]. Advocates for
the two-syndrome model cite the lack of prognos-
tic improvement in recent therapeutic trials with
DHF as compared to the success in SHF. This
would imply different disease processes. The
presence of ultrastructural changes in the cardiac
myocyte, and changes in matrix metalloproteinase
also support the latter view [236–238].Treatment
The key targets for therapy are active relaxation,
passive LV relaxation and myocardial fibrosis
[239]. The management of acute decompensated
diastolic HF should focus on correcting the precip-
itating factors such as myocardial ischaemia,
hypertensive crisis, acute rhythm disturbances,
hyperglycaemia and hyperinflation as well as
therapy to relieve pulmonary congestion. The
steep gradient of the diastolic pressure–volume
relationship means that a small change in a
LVEDV results in a significant change in LVEDP,
diuretics or nitrates should therefore be carefully
R
EV
IE
W
 A
RT
IC
LE
J Saudi Heart Assoc
2012;24:99–121
MAHARAJ 113
DIASTOLIC DYSFUNCTION AND HEART FAILUREconsidered when attempting to reduce LVEDV.
Hypertensive crisis are frequently encountered
in these patients. There have been several exciting
developments in the pharmacotherapy available
and the choice should be based on individual pa-
tient characteristics (Table 4) [240,241]. The use of
non-invasive ventilation is an effective therapy for
acute exacerbations of diastolic HF reducing hos-
pital mortality and the need for endotracheal intu-
bation [242,243]. Less recognized factors may also
play a role. For example obesity is a surrogate
for obstructive sleep apnoea (OSA). The cardio-
vascular abnormalities associated with OSA in-
clude LV hypertension, paroxysmal atrial
fibrillation and sympathetic activation. NIV will
reverse these abnormalities [244].
Beta blockers have been proposed for the treat-
ment of HFPreEF based on the assumption that
the rate lowering effect of prolonging diastole
would result in better LV filling [6]. There is data
from observational studies suggesting a differen-
tial benefit for beta blockers in HFPreEF compared
with patients with systolic impairment [245,246].
The sinus node If blocker Ivabradine offers the po-
tential to reduce heart rate without any effect on
contractility and may find a niche in patients with
HFPreEF [247]. Aldosterone is known to promote
ventricular fibrosis and collagen deposition. The
aldosterone antagonist spironolactone has been
shown to limit myocardial fibrosis [248]. Canre-
none is a spironolactone metabolite. In a small
randomized study, canrenone improved LV dia-
stolic performance without altering blood pres-
sure of LV mass significantly [249]. The trials
evaluating angiotensin receptor blockers cande-
sartan (CHARM PRESERVED trial), ibesartan (I-
PRESERVED trial), and the angiotensin-convert-
ing enzyme inhibitor peridopril (PEP CHF trial)
did not show any survival benefit when compared
with placebo [250–252].
The management of circulatory failure related to
diastolic dysfunction in critical illness is largely
supportive. Adequate fluid resuscitation is often
followed by drugs with a positive lusitropic effect.
In practice systolic and diastolic dysfunction often
co-exist and phosphodiesterase inhibitors and cal-
cium channel sensitisers are invaluable. Levosim-
endan is a calcium-sensitizing agent that mediates
effect through binding to Troponin C. This results
in increased myocardial contractility with minimal
increases in oxygen consumption. In this study,
levosimendan improved both systolic and dia-
stolic function in LPS treated animals and con-
trols. Levosimendan detaches from troponin C at
low calcium concentrations so its effect on diastoleis unexpected. It is probable that Toponin C may
have some effect on Troponin I even during
hyperphosphorylation [166]. The use of levosi-
mendin septic shock was first described in 2005
and since then there have been two randomised
clinical trials in this group of patients [253–255].
The first trial compared levosimendan with dobu-
tamine in 28 patients with septic shock [255]. In
both groups norepinephrine was use to maintain
mean arterial pressure. There were significant
improvements in cardiovascular performance
and organ function in the levosimendan group
(end-diastolic and end-systolic volume index and
left ventricular stroke work index) The second trial
involved thirty-five patients with septic shock,
ARDS and right ventricular failure [254]. Magnetic
resonance imaging showed an improved right
ventricular end diastolic volume index as well as
an improved right ventricular end systolic volume
index and right ventricular ejection fraction. These
were small studies not powered to show any mor-
tality benefit and there is insufficient evidence to
recommend the routine use of levosimendan in
sepsis induced diastolic dysfunction. A meta-anal-
ysis by Landoni et al. evaluated the role of levo-
simendan in critically ill patients [256]. The study
concluded a mortality benefit in favour of levosim-
endan (OR 0.74, 95% CI 0.62–089). This methodi-
cally rigorous analysis pooled 27 studies
involving patients with decompensated HF, elec-
tive cardiac surgery, acute myocardial infarction
and elective abdominal aortic aneurysm repair.
The heterogeneity of patients included in this
meta-analysis makes it difficult to extrapolate its
findings to severe sepsis.
Future trials should focus on the specific struc-
tural and functional abnormalities that occur in
HFPreEF patients. These include cardiomyocyte
hypertrophy, alterations in myocardial extracellu-
lar matrix metabolism, the shift in myocyte metab-
olism from glucose to free fatty acids, and the
higher expression and phosphorylation titin iso-
forms [257].Conclusion
Diastolic dysfunction and HF remain underap-
preciated in the peri-operative and critical care
environment. Epidemiological data predict that
diastolic HF will become the more frequently
encountered type of HF encountered in clinical
practice. Advances in echocardiography technol-
ogy have been instrumental in our understanding
of ventricular function. Currently, therapeutic
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2012;24:99–121options specific to this group of patients is limited
and mortality has remained unchanged. In con-
trast to patients with reduced EF, the prognosis
for those with HTPreEF has failed to improve in
the last three decades. The potential public health
burden should make diastolic dysfunction and
diastolic HF a priority.Conflict of interest
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